Tech Center 1600 • Art Units: 1600 1633
This examiner grants 58% of resolved cases
Joel D. Levin is an examiner in Tech Center 1600 and Art Unit 1600. He has 85 resolved cases, resulting in an allowance rate of 57.6 percent. This 57.6 percent rate indicates a balanced approach to examination, where more than half of the applications reach issuance. For practitioners, this figure suggests that success requires thorough technical arguments. The 85 resolved cases provide a solid foundation for evaluating his prosecution trends in Tech Center 1600.
The interview lift is 36.2 percent, which is a significant factor. This 36.2 percent increase suggests that direct communication is very effective at overcoming rejections in his docket. The median days to allowance is 1543, which is a long timeline of over four years. This 1543-day duration indicates that prosecution with this examiner requires a sustained effort and multiple rounds of response. Practitioners should use the 1543-day figure to manage client expectations and prioritize the 36.2 percent interview lift as a key strategy. The data suggests that while the baseline allowance rate is 57.6 percent, an interview can dramatically improve the odds of a successful outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17416962 | METHOD OF PRODUCING ENTERIC NEURONS AND USES THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 16312973 | BIO-ELECTRIC NOSE | Final Rejection | NORTHWESTERN UNIVERSITY |
| 17794735 | SERUM-FREE MEDIUM AND CULTURING METHOD SUITED FOR CULTURING BLOOD CELLS SUCH AS HUMAN HEMATOPOIETIC STEM CELLS | Non-Final OA | The University of Tokyo |
| 17369271 | METHODS FOR STIMULATING THE PROLIFERATION AND DIFFERENTIATION OF EUKARYOTIC CELLS | Final Rejection | PURDUE RESEARCH FOUNDATION |
| 17615382 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF CYSTATHIONINE BETA-SYNTHASE (CBS) ENZYME FOR TREATING CBS DEFICIENCY | Non-Final OA | Cornell University |
| 17776932 | METHODS OF CELL SELECTION | Final Rejection | LONZA LTD |
| 17721003 | METHODS OF PERFUSION CULTURING A MAMMALIAN CELL | Non-Final OA | Genzyme Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy